HIMS Hims & Hers Health, Inc.

BULLISH Impact: 6/10 8-K
Horizon weeks Filed Jun 2, 2026 Processed 3d 9h ago SEC 0001773751-26-000091
8-K material event: Items 1.01
Latest settled — T+1d
HIMS ▲ 0.00% at T+1d
LONG call ✗ call lost 0.00% · α vs SPY +0.69% · entry $27.51 → $27.51
Next anchor: T+5d in 4d
Currently $26.13 · -5.02% from $27.51 entry
Entry anchored
Jun 2, 05:04 AM ET
via Databento tick
T+1d
0.00%
call 0.00% · α +0.69%
$27.51
settled 2d ago
T+5d
call — · α —
in 4d
T+20d
call — · α —
in 26d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Hims & Hers completed its acquisition of Eucalyptus, an Australian digital health platform, expanding its presence to Australia, Canada, Germany, Japan, and the UK. The company concurrently amended its revolving credit facility to provide covenant relief and increase downstream investment capacity, supporting the deal. The acquisition reinforces management's long-term revenue target of $6.5 billion and Adjusted EBITDA of $1.3 billion by 2030.

Actionable Insight

The acquisition closes a key strategic international expansion, but without disclosed financials the near-term EPS impact is unclear. Monitor the next quarterly report for initial revenue contribution from Eucalyptus and any guidance update. The credit amendment provides balance sheet flexibility, reducing near-term financing risk.

Key Facts

  • Completed acquisition of Eucalyptus on June 2, 2026
  • Eucalyptus has served >850,000 customers to date
  • Amendment No. 3 to credit agreement provides 150-day clean-up period for Eucalyptus integration
  • Increased downstream investment capacity in non-loan party subsidiaries
  • Company reaffirms long-term targets of $6.5B revenue and $1.3B Adjusted EBITDA by 2030

Financial Impact

Acquisition extends global footprint but deal value not disclosed; credit facility remains $175 million with no material change to interest rates or covenants

revenueebitdasubscriber count

Risk Factors

  • Integration challenges across multiple new geographies and regulatory environments
  • Failure to achieve the aspirational 2030 revenue/EBITDA targets
  • Potential dilution if further debt or equity needed to fund international growth

Market Snapshot

Exchange
NYSE
Sector
Services-Offices & Clinics of Doctors of Medicine
Analyst Consensus
43% bullish (23 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001773751-26-000091
Exhibit: ex991pressreleaserercfeuc.htm0001773751-26-000091
Document: hims-20260529.htm0001773751-26-000091
Document: 0001773751-26-000091-index-headers.html0001773751-26-000091
Document: 0001773751-26-000091-index.html0001773751-26-000091
Document: 0001773751-26-000091.txt0001773751-26-000091
7 reports for HIMS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HIMS — sortable, filterable
Type Now
Jun 2, 2026
3d ago
8-K
BULLISH ★ 6/10
$27.51 $27.51· 0.00%▲ +0.69%$26.13 (−5.02%)
May 21, 2026
14d ago
8-K
NEUTRAL ★ 5/10
$23.75 $23.85▲ +0.42%▼ −0.16%$26.13 (+10.02%)
May 19, 2026
17d ago
8-K
MIXED ★ 6/10
$22.44 $23.04▲ +2.67%▲ +1.63%$26.13 (+16.44%)
May 11, 2026
24d ago
8-K
BEARISH ★ 7/10
$25.03 $25.03· 0.00%▲ +0.54%$26.13 (−4.39%)
Apr 28, 2026
5w ago
DEFA14A
NEUTRAL ★ 2/10
$27.91 $26.33▼ −5.66%▼ −5.65%$26.13 (−6.38%)
Mar 17, 2026
11w ago
Insider Cluster
NEUTRAL ★ 4/10
$24.98 $23.15▼ −7.33%▼ −5.93%$26.13 (+4.60%)
Mar 17, 2026
11w ago
Insider Cluster
NEUTRAL ★ 4/10
$24.98 $23.15▼ −7.33%▼ −5.93%$26.13 (+4.60%)
Showing 7 of 7

US Market Status

Market Open — Closes in 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access